Skip to main content
Premium Trial:

Request an Annual Quote

NetGenics Gets Funding for New Software Product

Premium

CLEVELAND--NetGenics Inc. has completed $6.5 million in financing for Synergy, the company's initial bioinformatics software product. A cross-platform, Java- and CORBA-based client-server software and services system designed for the pharmaceutical and biotechnology industries, Synergy has an architecture that is said to mirror the organization of multidisciplinary drug discovery teams and enable team members to collaborate and communicate research information efficiently.

Investors include Oxford Bioscience Partners, Venrock Associates, Incyte Pharmaceuti cals, Edgewater Private Equity Fund II, John Pappajohn, Crystal Internet Venture Fund, and Casdin Life Sciences Partners.

Synergy is designed to be more flexible and cheaper to maintain than traditional client-server software, according to NetGenics. The framework is a single software program that provides access to various data and software analysis tools in a common format. Synergy also addresses data security problems by running inside the user's firewall, controlling access to data by project team, and permanently archiving all data. Additional services available from NetGenics will include customization to facilitate access to legacy software and databases, training, and a help desk.

Filed under

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.